Liva Healthcare secures €24.5m funding - led by Verlinvest - to drive European leadership in digital chronic disease prevention and management
Liva Healthcare (“Liva”), a European market leader in scalable digital health coaching, has secured a new funding round of EUR 24.5 million, led by Verlinvest, the go-to investor for mission-driven entrepreneurs and category-defining global consumer brands. The investment will enable Liva to strengthen its position as a European leader in digital health and lifestyle coaching for chronic disease prevention and management.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210105005831/en/
Liva is a health tech company headquartered in Copenhagen and London with the mission to improve the lives of people at risk of, or living with, chronic conditions such as Type 2 diabetes, obesity, and heart diseases by driving positive behavioural change. Liva blends scalable health coaching focused on personal human relationships with an intuitive and user-friendly interface. Liva was founded in 2015 by the team behind independent health information portal NetDoctor.com.
The on-going Covid-19 pandemic has led to a significant shift in acceptance of remote healthcare by European consumers. This shift in acceptance and the subsequent patient behaviour has given Liva a significant increase in interest from public healthcare providers and life science companies in 2020.
Liva is used by clients such as Novo Nordisk, AXA Health, Amgen, City of Copenhagen, Bupa Australia and several other key players in public healthcare, insurance and life science industries globally. Liva is also a partner to NHS England on its world-leading National Diabetes Prevention Programme. Liva is currently operational in Britain, Australia, Ireland, Holland, Belgium, Denmark, Sweden, and Finland with operations currently being setup in Germany and Switzerland.
“This new funding, from one of Europe’s strongest purpose-led, consumer growth investors, will substantially accelerate our expansion in core European markets,” says André Sode, CEO of Liva Healthcare. “COVID-19 has demonstrated how effective remote digital health solutions can be. With healthcare providers around the world looking for scalable solutions to combat the rise in diabetes and obesity, we are ideally placed to support and have experienced a significant increase in interest as a result.”
“This investment represents a major new entry into digital health for Verlinvest, where technology is fuelling consumer revolutions,” says Simone Sallustio, Executive Director at Verlinvest. “Digital healthcare has been vital in getting treatment to patients during the pandemic and this trend will continue as effective virtual programmes give people more flexible healthcare options. Liva’s advanced technology and proven clinical outcomes set it apart from its competitors. In this exciting and rapidly evolving space, Liva’s experience and established partnerships represent a strategic choice for Verlinvest.”
About Liva Healthcare:
Liva Healthcare is a leading provider of scalable digital health coaching, delivering human-centric coaching through an advanced app to help people prevent and manage obesity, prediabetes, type 2 diabetes and cardiovascular diseases.
Verlinvest is a privately-owned family investment company based in Brussels with offices in New York, London, and Singapore.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TILRAY26.1.2021 12:02:10 CET | Press release
Tilray® Selected by French National Agency to Supply GMP-Certified Medical Cannabis Products in France
AQUA-LUNG26.1.2021 12:02:09 CET | Press release
Aqua Lung Welcomes World-Renowned Wildlife Photographer and Conservationist Paul Nicklen as a Global Ocean Ambassador
IL-XLEAR26.1.2021 10:17:11 CET | Press release
New Study Concludes Xlear Kills and/or Deactivates SARS-CoV-2; Efficacy Against New Variants
OWL-LABS26.1.2021 09:02:03 CET | Press release
Owl Labs Teams with Ingram Micro to Widen Distribution of the Meeting Owl Pro within Europe
MYHERITAGE26.1.2021 08:41:12 CET | Pressemeddelelse
MyHeritage udgiver farvegendannelsesfunktion for at give nyt liv til falmede farvefotos
CA-CREDENCE-MEDSYSTEMS26.1.2021 07:09:06 CET | Press release
Credence MedSystems Receives a Strategic Investment From One of the World’s Leading Pharmaceutical Companies
GA-AGCO25.1.2021 22:33:06 CET | Press release
AGCO Announces Organizational Update
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom